Profile - To The Moon

Nelliebear

Posts · 40Posts · 40
Following · 0Following · 0
Followers · 0Followers · 0

- NelliebearNelliebear
  ·2023-03-16
  Keep the faith
  Sorry, this post has been deleted
  1.71K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-20
  💪
  Sorry, this post has been deleted
  1.80K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-14
  👍
  Sorry, this post has been deleted
  3.85K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-12-14
  👍
  Sorry, this post has been deleted
  1.83K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-10-07
  👍
  Sorry, this post has been deleted
  1.48K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-22
  Keep going 👍
  Sorry, this post has been deleted
  1.72K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-20
  Keep going 👍
  Sorry, this post has been deleted
  1.75K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-19
  Keep going 💪
  U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder
  Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's gene therapy for the
  U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder
  1.59K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-15
  Keep going 💪
  Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants
  Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa
  Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants
  1.39K Comment
  Like
  Share
  Report
- NelliebearNelliebear
  ·2022-09-15
  💪 Keep going
  Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery
  Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever
  Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery
  1.32K Comment
  1
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4099579894850160","uuid":"4099579894850160","gmtCreate":1636476828583,"gmtModify":1636476828583,"name":"Nelliebear","pinyin":"nelliebear","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":40,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.40%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9943069212,"gmtCreate":1678970053837,"gmtModify":1678970057873,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"Keep the faith&nbsp;","listText":"Keep the faith&nbsp;","text":"Keep the faith","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9943069212","repostId":"2319635989","repostType":2,"isVote":1,"tweetType":1,"viewCount":1709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9926346415,"gmtCreate":1671475343437,"gmtModify":1676538542689,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"💪","listText":"💪","text":"💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9926346415","repostId":"2292878348","repostType":2,"isVote":1,"tweetType":1,"viewCount":1802,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919543,"gmtCreate":1670952901482,"gmtModify":1676538466261,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919543","repostId":"2291739039","repostType":2,"isVote":1,"tweetType":1,"viewCount":3854,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9921919295,"gmtCreate":1670952878417,"gmtModify":1676538466259,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9921919295","repostId":"2291146287","repostType":2,"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9915528738,"gmtCreate":1665076334724,"gmtModify":1676537553407,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9915528738","repostId":"2273255383","repostType":2,"isVote":1,"tweetType":1,"viewCount":1475,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9919401161,"gmtCreate":1663833732953,"gmtModify":1676537346296,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9919401161","repostId":"2269148689","repostType":2,"isVote":1,"tweetType":1,"viewCount":1716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910691126,"gmtCreate":1663610464666,"gmtModify":1676537300344,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 👍","listText":"Keep going 👍","text":"Keep going 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910691126","repostId":"2268990611","repostType":2,"isVote":1,"tweetType":1,"viewCount":1745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9910118672,"gmtCreate":1663574858396,"gmtModify":1676537293634,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9910118672","repostId":"2268403626","repostType":2,"repost":{"id":"2268403626","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1663387661,"share":"https://ttm.financial/m/news/2268403626?lang=&edition=fundamental","pubTime":"2022-09-17 12:07","market":"us","language":"en","title":"U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2268403626","media":"Reuters","summary":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the ","content":"<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA approves Bluebird bio's gene therapy for a rare neurological disorder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-09-17 12:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.</p><p>   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy <a href=\"https://laohu8.com/S/CALD\">$(CALD)$</a>, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\"</p><p> (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)</p><p>((mrinalika.roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4578":"CAR-T","BK4556":"基因编辑"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2268403626","content_text":"Sept 16 - The U.S. Food and Drug Administration has approved bluebird bio's    gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.   \"SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys\" with early, active Cerebral Adrenoleukodystrophy $(CALD)$, the company said in a statement, saying CALD is a \"devastating and fatal neurodegenerative disease.\" (Reporting by Mrinalika Roy and Jaiveer Shekhawatin in Bengaluru; Editing by Sriraj Kalluvila, Devika Syamnath and William Mallard)((mrinalika.roy@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"BLUE":1}},"isVote":1,"tweetType":1,"viewCount":1586,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934677665,"gmtCreate":1663250039257,"gmtModify":1676537236428,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"Keep going 💪","listText":"Keep going 💪","text":"Keep going 💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934677665","repostId":"2267500259","repostType":2,"repost":{"id":"2267500259","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1663238700,"share":"https://ttm.financial/m/news/2267500259?lang=&edition=fundamental","pubTime":"2022-09-15 18:45","market":"us","language":"en","title":"Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2267500259","media":"T-Reuters","summary":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Wa","content":"<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAditxt Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2022-09-15 18:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Aditxt Inc <adtx.o>:Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).</adtx.o></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","ADTX":"ADiTx Therapeutics","CGEM":"Cullinan Therapeutics","LABP":"Landos Biopharma, Inc.","BK4007":"制药","SANA":"Sana Biotechnology, Inc.","ONTF":"ON24, Inc.","BK4196":"保健护理服务","LHDX":"Lucira Health, Inc.","BK4023":"应用软件","BK4082":"医疗保健设备"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267500259","content_text":"Aditxt Inc :Aditxt Inc Files For Offering Up To 1.08 Million Shares Of Common Stock Together With Warrants To Purchase 1.08 Million Shares Of Common Stock.Aditxt Inc - Assumed Purchase Price For Each Share Of Common Stock And Accompanying Warrant Of $18.50.Further Company Coverage: Adtx.O. ((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1,"symbols_score_info":{"SANA":0.9,"CGEM":0.9,"APR":0.9,"ADTX":0.9,"LHDX":0.9,"LABP":0.9,"ONTF":0.9}},"isVote":1,"tweetType":1,"viewCount":1386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934984863,"gmtCreate":1663181239552,"gmtModify":1676537220433,"author":{"id":"4099579894850160","authorId":"4099579894850160","name":"Nelliebear","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099579894850160","idStr":"4099579894850160"},"themes":[],"htmlText":"💪 Keep going&nbsp;","listText":"💪 Keep going&nbsp;","text":"💪 Keep going","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9934984863","repostId":"1163730604","repostType":2,"repost":{"id":"1163730604","kind":"news","pubTimestamp":1662013072,"share":"https://ttm.financial/m/news/1163730604?lang=&edition=fundamental","pubTime":"2022-09-01 14:17","market":"us","language":"en","title":"Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery","url":"https://stock-news.laohu8.com/highlight/detail?id=1163730604","media":"Bloomberg","summary":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than sever","content":"<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Web Link</a>\n\n</div>\n","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Stock’s 13,000% Surge Creates Another US IPO Mystery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Stock’s 13,000% Surge Creates Another US IPO Mystery\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-01 14:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MEGL":"智富融资","ATXG":"盈喜集团","AMTD":"Amtd Idea","HKD":"尚乘数科"},"source_url":"https://www.bloomberg.com/news/articles/2022-09-01/chinese-stock-s-13-000-surge-creates-another-us-ipo-mystery?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163730604","content_text":"Addentax’s shares soared, bringing market cap to $20 billionCompany is now valued at more than several S&P 500 firmsAnother Chinese firm is baffling investors with massive gains on its first day of trading in the US, following on from stellar debuts for AMTD Digital Inc. and Magic Empire Global Ltd.Addentax Group Corp.soared as much as 13,031% on Wednesday in its debut session, triggering more than 20 volatilityhalts. Its market capitalization has ballooned to $20 billion, making it bigger than about a third of S&P 500 Index members.Addentax, which lists garment manufacturing and logistics services among its key businesses, is at least the eighth firm this year from Hong Kong or China to experience similarly surprising moves following initial public offerings in the US. The Nevada-based holding company did not immediately respond to an emailed seeking comment and calls to numbers listed on its website went unanswered.AMTD Digital and Magic Empire, both of which are financial services companies based in Hong Kong, made headlines earlier this quarter as shares mysteriously soared by thousands of percent despite opaque fundamentals, before the rallies fizzled out. AMTD Digital Inc. at one pointbecamebigger than Goldman Sachs Group Inc.“The driving force behind the Addentax Group’s price seemingly deliberately duplicates the story of HKD and MEGL, which also experienced an unprecedented share-price frenzy recently,” said Hebe Chen, an analyst at IG Markets Ltd.She said the commonality between them includes the fact that they all come from traditional industries and have not-so-stellar financials.Listed originally in 2015, when it identified itself as ashell company, Addentax in December 2016 acquired a key stake in its current major operating entity called Yingxi Industrial Chain Group Co. The company was trading on an over-the-counter market for US stocks called OTCQB Marketplace prior to its listing on the Nasdaq this week.Sponsored ContentHow Will Corporates Shape the Path to a Cleaner Future?YokogawaAccording to itsprospectus, Addentax used the same underwriter -- Network 1 Financial Securities Inc. -- as Magic Empire.Modest RevenuesLike Magic Empire and AMTD Digital, Addentax has modest revenues that allow for relaxed disclosure requirements under US laws. For the year ended March, revenue dropped 49% to $12.7 million but it turned a profit, according to the prospectus.Chen from IG Markets says it is “more than likely” that the Addentax will follow the pathway of AMTD and Magic Empire soon. The latter two have lost more than 90% from their respective peaks.","news_type":1,"symbols_score_info":{"HKD":0.9,"MEGL":0.9,"AMTD":0.9,"ATXG":0.9}},"isVote":1,"tweetType":1,"viewCount":1324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}